Get the Stockscreener App
1.21
2.42%
-0.03
After Hours:
1.24
0.03
+2.48%
NanoViricides Inc stock is traded at $1.21, with a volume of 227.52K.
It is down -2.42% in the last 24 hours and down -12.32% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.24
Open:
$1.27
24h Volume:
227.52K
Relative Volume:
0.72
Market Cap:
$26.10M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-1.7286
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
-6.92%
1M Performance:
-12.32%
6M Performance:
-9.70%
1Y Performance:
-19.33%
1-Day Range:
$1.21
$1.30
1-Week Range:
$1.21
$1.39
52-Week Range:
$0.94
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.21 | 26.74M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
Is NanoViricides Inc. stock a top momentum playRisk Management & Intraday High Probability Alerts - Улправда
Is NanoViricides Inc. stock positioned for secular growthProfit Target & High Return Trade Opportunity Guides - Улправда
Is NanoViricides Inc. stock cheap at current valuationMarket Performance Recap & Weekly Return Optimization Plans - Улправда
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Asbury Park Press
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
NanoViricides advances Phase 2 trials for broad-spectrum antiviral NV-378 in $17B market: analysts - Proactive financial news
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - Lubbock Avalanche-Journal
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive - Enterprise News
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - Worcester Telegram
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides - SouthCoastToday.com
NanoViricides Dual Track Clinical Strategy Explained by a Research ReportBroad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses - SouthCoastToday.com
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd - Siskiyou Daily News
Belarus frees Nobel laureate Ales Bialiatksi and opposition figure Maria Kolesnikova from prison, rights group confirms - Barchart.com
Applied Digital, Benchmark, Knowles, Cognex, and Flex Stocks Trade Down, What You Need To Know - Barchart.com
Shootin' the Bull about wait and see - Barchart.com
2 Small-Cap Biotechs That Could Reward Patient Investors - Investing.com
EU indefinitely freezes Russian assets to stop Moscow-friendly Hungary and Slovakia from vetoing their use for Ukraine - Barchart.com
2 Small-Cap Biotechs That Could Reward Patient Investors - MarketBeat
Is Clorox Stock Underperforming the S&P 500? - Barchart.com
Is J.B. Hunt Transport Services Stock Outperforming the Dow? - Barchart.com
Americans, including many in Trump’s base, overwhelmingly see higher holiday prices than normal, an AP-NORC poll finds - Barchart.com
Is Hologic Stock Outperforming the Nasdaq? - Barchart.com
How Is VeriSign’s Stock Performance Compared to Other Software Stocks? - Barchart.com
NanoViricides Holds 2025 Annual Stockholders Meeting - MSN
US sanctions 3 nephews of Venezuelan President Maduro as Trump further ramps up pressure on South American nation - Barchart.com
This AI Stock Has 45% Upside Potential and No One Is Talking About It Yet - Barchart.com
Stocks in play: Goodfood Market Corp. - Barchart.com
How Is Best Buy's Stock Performance Compared to Other Specialty Retail Stocks? - Barchart.com
Corpay Stock: Is CPAY Underperforming the Technology Sector? - Barchart.com
1 Profitable Stock to Target This Week and 2 We Avoid - Barchart.com
3 Reasons EYE is Risky and 1 Stock to Buy Instead - Barchart.com
3 Reasons to Sell SJM and 1 Stock to Buy Instead - Barchart.com
Why Inspire Medical Systems (INSP) Stock Is Up Today - Barchart.com
Is Veralto Corporation Stock Underperforming the S&P 500? - Barchart.com
Is Steel Dynamics Stock Outperforming the Dow? - Barchart.com
Is PTC Stock Underperforming the Nasdaq? - Barchart.com
Is Invitation Homes Stock Underperforming the Dow? - Barchart.com
Is Teradyne Stock Outperforming the Nasdaq? - Barchart.com
Is Cardinal Health Stock Outperforming the Nasdaq? - Barchart.com
Chewy (NYSE:CHWY) Surprises With Q3 CY2025 Sales - Barchart.com
Is FirstEnergy Stock Underperforming the S&P 500? - Barchart.com
How Is Rollins’ Stock Performance Compared to Other Cyclical Stocks? - Barchart.com
GBPUSD Extends Rally As Bullish Impulse Builds - Barchart.com
3 Inflated Consumer Stocks That Concern Us - Barchart.com
Commerce (CMRC): Buy, Sell, or Hold Post Q3 Earnings? - Barchart.com
AeroVironment (NASDAQ:AVAV) Beats Q3 CY2025 Sales Expectations But Stock Drops - Barchart.com
Apple Stock Marks a Solid Comeback. Is AAPL a Buy, Sell, or Hold for 2026? - Barchart.com
Marvell Soars 32% in 3 Months — Is MRVL Stock a Buy, Sell, or Hold? - Barchart.com
AeroVironment: Fiscal Q2 Earnings Snapshot - Barchart.com
Why Are Revolve (RVLV) Shares Soaring Today - Barchart.com
Upwork (UPWK) Stock Is Up, What You Need To Know - Barchart.com
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):